Baseline characteristics for patients with digital X-ray radiogrammetry (dxr-BMD) data available and those without dxr-BMD data.
| Characteristics | Patients in Study, n = 76 | Patients with No dxr-BMD Data, n = 44 | p |
|---|---|---|---|
| Demographic | |||
| Age, yrs, mean (SD) | 46.3 (11.0) | 46.3 (11.6) | 1.00 |
| Female, n (%) | 35 (46.1) | 12 (27.2) | 0.04* |
| Clinical | |||
| Duration of PsA, yrs, mean (SD) | 6.4 (6.3) | 6.9 (6.9) | 0.94 |
| Infliximab treatment, n (%) | 39 (51.3) | 21 (47.7) | 0.70 |
| Methotrexate at baseline, n (%) | 37 (49.7) | 22 (50.0) | 0.88 |
| Corticosteroids at baseline, n (%) | 8 (10.5) | 7 (15.9) | 0.39 |
| Tender joint count (0–66; median) | 23.5 (13.3) | 23.4 (14.0) | 0.97 |
| Swollen joint count (0–66) | 14.1 (7.2) | 13.4 (9.1) | 0.65 |
| C-reactive protein, mg/l (median) | 23.1 (33.0) | 20.9 (35.4) | 0.62 |
| HAQ-DI (0–3; median) | 1.1 (0.6) | 1.2 (0.6) | 0.60 |
| PASI (0–72; median) | 67.1 (83.2) | 78.6 (98.9) | 0.52 |
| Modified TSS (0–528) | |||
| Mean (SD) | 32.0 (55.2) | 33.2 (55.9) | |
| Median (25th–75th percentile) | 8.0 (2.0–44.3) | 10.5 (1.8–39.8) | 0.78 |
↵* p < 0.05. PsA: psoriatic arthritis; PASI: Psoriasis Area and Severity Index score; HAQ-DI: Health Assessment Questionnaire Damage Index; TSS: Total Sharp Score.